- Lobbying
- patient AND pocket
Lobbying Arrangements Results for 'Patient Pocket'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details General lobbying related to medical benefits, prescription costs, underinsured individuals, access to healthcare. |
Patient Access Network (PAN) Foundation
|
McAllister & Quinn, LLC | |||
Details FY24 Funding, NIH FY24 Funding, CDC FY24 Funding, HRSA Coverage, Access, Patient Out of Pocket Cost Issues |
Accessia Health (formerly PATIENT SERVICES INCORPORATED)
|
Health and Medicine Counsel, LLC | |||
Details H.R. 7609, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, FY2021, provisions on operating room safety. Department of VA procurement issues. |
Patient Pocket LLC
|
DLA Piper LLP (US) | |||
Details FY24 Funding, NIH and NCSDR FY24 Funding, CDC and CDEA Program FY24 Funding, DOD and PRMRP Coverage, Access, and Patient Out of Pocket Costs New Products Review, Approval, and Accessibility |
Project Sleep
|
Health and Medicine Counsel, LLC | |||
Details FY24 CDC Funding FY24 HRSA Funding Patient Access, Coverage, and Out of Pocket Cost Issues Rural Care |
Hope Charities
|
Health and Medicine Counsel, LLC | |||
Details Capping Medicare Part D Out of Pocket Costs; Smoothing Medicare Part D Out of Pocket Costs; Medicare Part B and Part D drug pricing; Part D patient protections; Medicare quality measures for and st... |
Alliance for Aging Research
|
Venable LLP | |||
Details FY24 Funding, NIH FY24 Funding, CDC and CDEA Program FY24 Funding, DOD and PRMRP Health Equity Coverage, Access, and Patient Out of Pocket Costs |
The National Pancreas Foundation
|
Health and Medicine Counsel, LLC | |||
Details Issues involving international trade, including IP protections Issues related to corporate tax reform Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform... |
Pfizer Inc.
|
Roberti Global (fka Roberti White, LLC) | |||
Details Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out of pocket costs for patients. HELP Copays Act HR830, S1375 FY 2025 NBPP HHS response to HIV+Hep vs Bac... |
CROHN'S & COLITIS FOUNDATION
|
in-house lobbying | |||
Details Medicare Part D Smoothing; Medicare Part D Out of Pocket Costs; Adding Dental, Vision, and Hearing benefits to Medicare; Vaccine co-pay parity for Medicare Part D and Part B; H.R. 502/S. 87 - Medic... |
Patient Access Network Foundation
|
Faegre Drinker Biddle & Reath LLP | |||
Details Capping Medicare Part D Out of Pocket Costs; Smoothing Medicare Part D Out of Pocket Costs; Broadening the Part D Low-Income Subsidy; Medicare Part B and Part D drug pricing; Part D appeals process... |
Alliance for Aging Research
|
Faegre Drinker Biddle & Reath LLP | |||
Details Transparency Policy Issues, Medicare Part D, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills); H.R. 2666 MVP Act,... |
Astellas Gene Therapies, Inc. a Delaware Corporation
|
in-house lobbying | |||
Details Safe step act, help copays act, chronic disease education and awareness program at CDC. CDC chronic disease education and awareness program - appropriations! Inflation Reduction Act and Part D out ... |
NATIONAL PSORIASIS FOUNDATION
|
in-house lobbying | |||
Details HIV/AIDS Domestic Programs: Ryan White HIV/AIDS Program, including the AIDS Drug Assistance Program, CDC HIV prevention programs, NIH AIDS Research, HOPWA AIDS housing, Ending the HIV Epidemic Ini... |
THE AIDS INSTITUTE
|
MR. CARL SCHMID | |||
Details Affordable Care Act, all provisions and related regulations, including reporting (IRC 6055 and 6056); employer mandate; wellness issues; out-of-pocket (OOP) limits, nondiscrimination, ADA and GINA,... |
The ERISA Industry Committee
|
DYKEMA GOSSETT PLLC | |||
Details Telehealth - Extending Flexibilities; Maternal Health; Affordability; Provider Network Challenges (Contract Dispute); Site Neutral Payment Policies; Prior Authorizations, Transparency in Coverage; ... |
BLUECROSS BLUESHIELD OF TENNESSEE
|
in-house lobbying | |||
Details RetireSafe joined with the National Energy and Utility Affordability Coalition to urge the House and Senate Appropriations Committees to support at least $4.7 billion for the FY 2016 Low Income Hom... |
RetireSafe
|
Mr. ALFRED W. CORS, JR | |||
Details Public Health Education and Research Program on Tourette Syndrome at the Centers for Disease Control and Prevention and CDC Funding Broadly - Fiscal Year 2023, 2024 and 2025 National Institutes of ... |
Tourette Association of America
|
in-house lobbying | |||
Details Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation... |
Astellas Pharma US, Inc.
|
in-house lobbying | |||
Details Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement health care reform legislation Follow developments within the Administration relating to globa... |
WYETH
|
in-house lobbying | |||
Details Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimburs... |
Genentech
|
Capitol Counsel LLC | |||
Details Support legislation to reform Congressional Budget Office scoring of health care legislation Oppose drug importation proposals Support diversity in clinical trial policy Support medical device chan... |
California Life Sciences
|
in-house lobbying | |||
Details Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act whi... |
Allergan USA, Inc.
|
in-house lobbying | |||
Details Issues related to drug pricing, drug shortages, and the drug supply chain, including support for the following bills: the Protecting Patients Against PBM Abuses Act (H.R. 2880), the Transparency an... |
American Society of Health-System Pharmacists
|
in-house lobbying | |||
Details Appropriations for the National Breast and Cervical Cancer Early Detection Program Appropriations for breast cancer research Appropriations for cancer prevention and control Policies related to ac... |
Susan G. Komen
|
ARTEMIS POLICY GROUP LLC | |||
Details Issues related to Medicare Part D and prescription drug pricing and patient access, including monitor implementation of related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 11... |
Astellas Pharma US, Inc.
|
Capitol Counsel, LLC | |||
Details Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; Covid Vaccines S. 150 - Affordable Prescriptions for Patients Act of 2023 A bill to amend the Federal Trade Commission Act to prohib... |
BCBSM, Inc.
|
in-house lobbying | |||
Details out-of-pocket costs, drug prices, utilization management, prior authorization, step therapy, clinical trial diversity, COVID-19 therapeutics, pharmacist scope of practice, telehealth extensions , a... |
ARTHRITIS FOUNDATION
|
in-house lobbying | |||
Details Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM polici... |
Novartis
|
BGR Government Affairs | |||
Details Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy. Share our concerns and support with PA congressional... |
Life Sciences Pennsylvania
|
in-house lobbying | |||
Details FY24 appropriations for the National Cancer Institute, specifically funding for programs related to the Childhood Cancer STAR Reauthorization Act and the Childhood Cancer Data Initiative (CCDI); FY... |
The Leukemia & Lymphoma Society
|
in-house lobbying | |||
Details Affordable Care Act, all provisions and related regulations, including reporting (IRC 6055 and 6056); employer mandate; wellness issues; out-of-pocket (OOP) limits, nondiscrimination, PCORI & comp... |
The ERISA Industry Committee
|
in-house lobbying | |||
Details H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus pa... |
The Michael J. Fox Foundation For Parkinson's Research
|
in-house lobbying | |||
Details (1)Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (2)Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (3)Issues rel... |
AETNA INC.
|
in-house lobbying | |||
Details Public Law 115-271-SUPPORT for Patients and Communities Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enfor... |
Healthcare Distribution Alliance f/k/a Healthcare Distribution Management Assoc.
|
Brown Rudnick LLP | |||
Details FY24 Labor, HHS, and Education appropriation bill related to funding for biomedical research, NBCCEDP, cancer prevention and control, and related cancer services and report language related to acce... |
The Susan G. Komen Breast Cancer Foundation, Inc. dba Susan G. Komen
|
in-house lobbying | |||
Details Supporting the following funding levels in FY24 appropriations bills: LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.6 billion for the Centers for Disease Control and Pr... |
NATIONAL MULTIPLE SCLEROSIS SOCIETY
|
in-house lobbying | |||
Details CBO modeling Drug Pricing Fiscal year 2024 Appropriations H.R. 5376, Inflation Reduction Act H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024 Importation Value of Med... |
NOVARTIS
|
in-house lobbying | |||
Details -H.R. 5860, Continuing Appropriations Act, 2024 and Other Extensions Act, support passage. -H.R. 6363, Further Continuing Appropriations and Other Extensions Act, support passage. -Labor, Health an... |
Epilepsy Foundation
|
in-house lobbying | |||
Details Provider Directories; Medicaid Redeterminations; Draft Duals Legislation; IRA Copay Smoothing; MA Health Equity Index HR 2880 (118th Congress), Protecting Patients Against PBM Abuses Act, by Rep. ... |
GuideWell Mutual Holding Corporation
|
in-house lobbying | |||
Details Insulin Copay Caps, Drug Pricing, Pharmacy Benefit Manager (PBM) Reform, Generic Drug Manufacturing Senate Finance Committee PBM Reform Framework H.R. 5378 - The Lower Costs, More Transparency Ac... |
HIGHMARK, INC.
|
in-house lobbying | |||
Details Affordable Care Act (ACA), ACA subsidies; Telehealth; Mental Health, Mental Health Rule, Youth Mental Health Access; Site Neutrality/Site neutral payment reform and Fair Hospital Billing; Transpare... |
BLUE CROSS BLUE SHIELD OF MICHIGAN
|
in-house lobbying | |||
Details Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutriti... |
American Cancer Society Cancer Action Network, Inc.
|
in-house lobbying | |||
Details Affordable Care Act (ACA); ACA Subsidies; Telehealth; Mental Health; Mental Health Rule; Youth Mental Health Access; Site Neutrality/Site Neutral Payment Reform and Fair Hospital Billing; Transpare... |
Blue Cross and Blue Shield of Florida, Inc.
|
in-house lobbying | |||
Details Insulin Out of Pocket Costs; Covid Therapeutics; Generics Access; Gene Therapy S. 150 - Affordable Prescriptions for Patients Act of 2023 A bill to amend the Federal Trade Commission Act to prohi... |
Blue Cross and Blue Shield Association
|
in-house lobbying |